Govzilla

"FY2018 warning letters continued to focus on contracted activities, an area of focus that in my opinion will continue into the foreseeable future."
BARBARA W. UNGER

An Analysis of FDA FY2018
Drug GMP Warning Letters

Identify new FDA inspection trends to proactively address similar situations in your company.

Topics of this report include:

First, please provide some details so that we deliver your report